Publications by authors named "Glynn Morrish"

Claim this Profile
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.
Guy Ludbrook, Nathan Bryson, Beatrix Taylor, Jasna Hocevar-Trnka, Matthew W Johnson, Glynn Morrish

J Clin Psychopharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.
Keith Dredge, Todd V Brennan, Edward Hammond, Jason D Lickliter, Liwen Lin, Glynn Morrish

Br J Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients.
Giovanni Di Perri, Bruce Green, Glynn Morrish, Andrew Hill, Gerd Faetkenheuer

HIV Clin Trials· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women.
J G Coen van Hasselt, Bruce Green, Glynn A Morrish

Pharm Res· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.
Sarah C McLeay, Glynn A Morrish, Carl M J Kirkpatrick, Bruce Green

Clin Pharmacokinet· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of obesity on drug pharmacokinetics in humans.
Glynn A Morrish, Manjunath P Pai, Bruce Green

Expert Opin Drug Metab Toxicol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Encouraging the move towards predictive population models for the obese using propofol as a motivating example.
Sarah C McLeay, Glynn A Morrish, Carl M Kirkpatrick, Bruce Green

Pharm Res· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.
Glynn A Morrish, David J R Foster, Andrew A Somogyi

Br J Clin Pharmacol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis